Wuhan opens the negotiation of insulin quantity and price, and the pattern of hospital market medication may have new changes

[pharmaceutical network industry trends] recently, Wuhan pharmaceutical machinery centralized purchasing service platform released a notice on pricing of insulin drugs in Wuhan Among them, before January 9, the enterprises participating in the on-site negotiation need to complete the check-in; clear drug purchase scope, grouping principle, price negotiation rules, quotation methods, etc This is a new progress after Wuhan started to purchase 45 varieties with high clinical dosage, such as omeprazole, lansoprazole, budesonide, and zuocarnitine, and first incorporated insulin into the volume procurement in early December last year
Among them, it is worth noting that in terms of the negotiation rules, when the product specifications of the same group and the same enterprise are ≥ 2, and the quotation is lower than 5% of the national provincial low price (weighted decrease), 70% of the procurement volume of this group of products in Wuhan in 2018 is the agreed procurement volume, and when the quotation is lower than 10% of the national low price, 90% of the procurement volume of this group of products in Wuhan in 2018 is the agreed procurement volume Purchase volume In addition, the notice also shows that the scope of drug procurement is: human insulin and insulin like drugs that are online in "Hubei provincial centralized procurement service platform for medical devices" and have transaction volume in medical institutions in Wuhan area before June 30, 2019 It should also be noted that in addition to the agreed purchase quantity, the remaining purchase quantity will be used as the replacement quantity If the reduction and weighted reduction are less than 5%, more than 50% of the purchase quantity of the product in Wuhan in 2018 will be used as the replacement quantity According to the previously released grouping and purchase volume information, the total agreed purchase volume is about 1.7057 million, of which insulin-like drugs account for 68% The huge purchase volume in Wuhan once again makes the nearly 10 billion diabetes drug market begin to boil Data shows that in 2018, the market scale of chemical drugs used in public hospitals in key provinces and cities rose to 6.77 billion yuan Insulin and its similar drugs, as the main therapeutic drugs, have a market share of more than 37% In 2018, the sales volume of public hospitals in key provinces and cities exceeded 2.5 billion yuan In recent years, imported Insulin and its analogues have been in the leading position, but domestic enterprises such as Ganli pharmaceutical, Jiangsu Wanbang biochemical and Tonghua Dongbao are also speeding up market development In fact, the whole pharmaceutical industry chain is in the period of reconstruction under the influence of relevant policies such as volume purchase However, with the implementation of the new regulations on volume purchase in Wuhan, it will not only change the drug use pattern in Wuhan hospital market, but also bring new changes to the national drug price system In the future, integration between platforms, upstream and downstream convergence and cross-border cooperation will become increasingly frequent In the face of the increasingly complex environment, the relevant enterprises must follow up the policy, correctly treat the problems and challenges in the pharmaceutical market, seek benefits and avoid disadvantages, and take a more active attitude to deal with the challenges in the new era In the next period of time, it will be the top priority for pharmaceutical enterprises to continue to look for new business models and new profit growth points.